Literature DB >> 8297741

pS2 and response to adjuvant hormone therapy in primary breast cancer.

F Spyratos1, C Andrieu, K Hacène, P Chambon, M C Rio.   

Abstract

We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in patients who received hormone therapy, in whom pS2 status was also predictive of the response to therapy.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8297741      PMCID： PMC1968674          DOI： 10.1038/bjc.1994.73

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  17 in total

1.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

2.  Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence.

Authors:  M Berry; A M Nunez; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

4.  Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

Authors:  M C Rio; J P Bellocq; B Gairard; U B Rasmussen; A Krust; C Koehl; H Calderoli; V Schiff; R Renaud; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Prediction of relapse and survival in breast cancer patients by pS2 protein status.

Authors:  J A Foekens; M C Rio; P Seguin; W L van Putten; J Fauque; M Nap; J G Klijn; P Chambon
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

6.  Hormone-sensitive gene expression in breast tumours.

Authors:  S J Wysocki; E Hahnel; S P Wilkinson; V Smith; R Hahnel
Journal:  Anticancer Res       Date:  1990 Jan-Feb       Impact factor: 2.480

7.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Authors:  L H Schwartz; F C Koerner; S M Edgerton; J M Sawicka; M C Rio; J P Bellocq; P Chambon; A D Thor
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

8.  Immunoradiometric assay of pS2 protein in breast cancer cytosols.

Authors:  J Goussard; C Lechevrel; G Roussel; H Cren; O Bera; M Sala
Journal:  Clin Chem       Date:  1991-10       Impact factor: 8.327

9.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

Authors:  J A Henry; N H Piggott; U K Mallick; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640
View more
  4 in total

1.  Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.

Authors:  T van Agthoven; T L van Agthoven; A Dekker; P J van der Spek; L Vreede; L C Dorssers
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

2.  Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.

Authors:  P Pujol; J P Daurès; J P Brouillet; T Maudelonde; H Rochefort; J Grenier
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

3.  TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.

Authors:  Felicity E B May; Bruce R Westley
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

4.  Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.

Authors:  Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.